Mammoth Biosciences logo

Mammoth Biosciences Funding & Investors

Mammoth Biosciences is a biotechnology company based in South San Francisco, California developing diagnostic tests using CRISPR-Cas12a. The company was founded in 2017 by Jennifer Doudna, Janice Chen, Trevor Martin, and Lucas Harrington of the University of California, Berkeley. Mammoth signed agreements in December 2019 and January 2020 with Horizon Discovery to combine Mammoth's intellectual property in CRISPR with Horizon's expertise in Chinese hamster ovary cells. Also in 2020, both Mammoth Biosciences and Sherlock Biosciences from the Broad Institute used their similar CRISPR technologies to develop tests for COVID-19. The technology, which is owned under the trademark of DETECTR BOOST, has been contracted to be manufactured by Merck & Co.

https://mammoth.bio/

Total Amount Raised: $264,544,992

Mammoth Biosciences Funding Rounds

  • Series D

    $150,000,000

    Series D Investors

    Redmile Group
    Mayfield Fund
    NFX
    Foresite Capital
    Senator Investment Group
    Decheng Capital
    Greenspring Associates
    Plum Alley
    Sixth Street
    Bradley Horowitz
    Tachyon Ventures
    Jason Haider
  • Series C

    $45,000,000

    Series C Investors

    Foresite Capital
    NFX
    Redmile Group
    Decheng Capital
    Amazon
    Sixth Street
    Mayfield Fund
  • Series B

    $45,000,000

    Series B Investors

    Decheng Capital
    Mayfield Fund
    NFX
    Pacific 8 Ventures
    Plum Alley
    aMoon Fund
    Verily
    Brook Byers
    Tachyon Ventures
  • Series A

    $23,000,000

    Series A Investors

    Mayfield Fund
    NFX
    8VC
    Tectonic Capital
    Plum Alley
    Jeff Huber
    Tim Cook
    DHVC (Danhua Capital)
    SV Angel
    Tachyon Ventures
  • Seed

    $1,425,000

    Seed Investors

    NFX
    K50 Ventures
  • Pre Seed

    $120,000

    Pre Seed Investors

    NFX
    Wireframe Ventures
    8VC
    Mayfield Fund
    AME Cloud Ventures
Funding info provided by Diffbot.